Experimental senolytic peptide targeting the FOXO4-p53 interaction
FOXO4-DRI
aka FOXO4 D-retro-inverso peptide · FOXO4-p53 interfering peptide
User reports
approximate — combined from two independent Reddit reads
Men 45–60
0 men aged 45–60
No reports in this group yet.
All men
1 man
small sample · n = 1Outcome no effect 1 of 1
Side effects fatigue 1 of 1 · injection site 1 of 1
Everyone
11 people
- Positive: 2 of 11 (18%)
- Mixed: 1 of 11 (9%)
- Negative: 2 of 11 (18%)
- No effect: 2 of 11 (18%)
- Unclear: 4 of 11 (36%)
| Item | Reports |
|---|---|
| Other | 2 of 11 (18%) |
| Energy | 1 of 11 (9%) |
| Fat loss | 1 of 11 (9%) |
| Inflammation | 1 of 11 (9%) |
| Sleep | 1 of 11 (9%) |
| Item | Reports |
|---|---|
| Injection site | 3 of 11 (27%) |
| Fatigue | 2 of 11 (18%) |
| Blood pressure | 1 of 11 (9%) |
| Headache | 1 of 11 (9%) |
| Other | 1 of 11 (9%) |
| Item | Reports |
|---|---|
| Cost | 2 of 11 (18%) |
| Other | 1 of 11 (9%) |
User reports are anecdata, not evidence: self-selected, unverified, often combined with other compounds.
In their words
“nodules were much more pliable, ROM increased, and pain and inflammation were significantly lower”
“my blood pressure peaked at 203/103”
“14-15/07/26: no peptides to observe 72 hour pulse for FOXO4-DRI. Bit more fatigue than usual. Nothing else to report.”
“I took Foxo4-dri over 4 years ago. It was impressive, I felt 15 years younger in alot of respect.”
“I didn't notice fatigue that some point out, but the injection site was quite sore for about 18hrs.”
Read summaries and method notes
Read 1. No verified man aged 45–60 (n=0). Two specific firsthand reports: one described more pliable fibrotic nodules, better range of motion and less pain/inflammation (later stacked with SS-31, KLOW and MOTS-c), the other a severe sustained blood-pressure rise to about 203/103 after two injections, needing extra medication. Blood pressure is the most consequential signal in this tiny corpus.
Read 2. No man aged 45–60; the only clearly male user was in his late 30s and reported fatigue and two days of injection pain after 80 mg in a week, with no noticeable benefit. Nine users from 6 threads: mostly unclear (4) or no effect (2), plus 1 positive ("felt 15 years younger"), 1 mixed (5–11 lb weight loss with lethargy and headaches) and 1 negative. Commonest side effects: sore injection sites for 18 hours to several days, fatigue, headache, over very short 5–21-day cycles. Two limited or ended cycles because 100 mg protocols cost about $1,200.
Note 1. Only two verified firsthand reports were sufficiently specific. One positive course became stacked, limiting attribution.
Note 2. No men 45-60 (a 67-year-old did not state sex). r/BodyHackGuide and promotional guides were excluded. A third-party report about a 46-year-old long-COVID subject was not counted.
Each read counted people independently. Overlap between the two reads is estimated from shared threads and removed; counts are approximate. How we count.
Summary
D-retro-inverso peptide that disrupts the FOXO4-p53 interaction holding senescent cells alive. Induced apoptosis selectively in senescent cells in experiments, but human systemic selectivity is unknown. Independent groups have published additional preclinical studies; they do not exactly replicate every original endpoint. Human treatment trials or published human administration were not found.
Proposed mechanism
The FOXO4-p53 axis in senescence. Senescent cells resist apoptosis by sequestering p53 in the nucleus via FOXO4 binding. FOXO4 localization and expression vary by tissue and context. The FOXO4-p53 complex keeps p53 locked away from mitochondria, preventing it from triggering intrinsic apoptosis. The peptide binds p53, and cell-culture selectivity does not establish safety in healthy human tissues.
D-retro-inverso (DRI) design. The peptide sequence is reversed and all L-amino acids swapped to D-amino acids. The design is intended to alter peptide stability and binding; human half-life, biodistribution and clinical advantage have not been established.
Selectivity rationale. FOXO4 expression and localization are context-dependent; a universal two-to-fivefold rule is not established. The peptide competitively disrupts FOXO4-p53 → p53 is released → p53 translocates to mitochondria → cytochrome c release → apoptosis. Selectivity in cultured cells cannot establish selectivity throughout a human body. This is the theoretical selectivity story. Whether it holds at therapeutic doses in humans is completely unknown.
Safety
- Human adverse-event rates, pharmacokinetics, immunogenicity and contraindications not established.
- A pulmonary-hypertension mouse study reported harmful pulmonary vascular effects.
- Selectivity in cultured cells does not establish systemic human safety.
From labels, regulators and trials. No signal in small studies ≠ safe.
Legal status
US FDANot approved
Approval not found; 503A category entry not found. FOXO4-DRI was not found in the May 14, 2026 FDA 503A nomination categories or the July 23–24, 2026 PCAC agenda; no peptide-specific meeting outcome applies. Source
checked 2026-11-13WADA 2026Likely prohibited (S0)
Prohibited under S0 if unapproved for human therapeutic use; rule-based classification, not individually named. Source
checked 2026-11-13EU
EMA/EU marketing authorization not found; country-specific rules not established in this review.
checked 2026-11-13Evidence D senolytic anti-ageing
D stands. Cell, tissue and mouse data only (including one harmful mouse study); no human trial.
Human trials · 0
No human trials found for the marketed use.
Dose ranges
Reported ranges from labels and studies, with context. Not a recommendation.
No data.
Editorial ratings EDITORIAL
Editors’ judgement, 0–5. Opinion, not data; separate from grade and user score.
Sources
- fda.gov/media/94155/download
- wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- pubmed.ncbi.nlm.nih.gov/28340339/
- pubmed.ncbi.nlm.nih.gov/31959736/
- pubmed.ncbi.nlm.nih.gov/39994346/
- pubmed.ncbi.nlm.nih.gov/41625068/
- pubmed.ncbi.nlm.nih.gov/40593617/
- pubmed.ncbi.nlm.nih.gov/39025385/
- pubmed.ncbi.nlm.nih.gov/36515093/
- pmc.ncbi.nlm.nih.gov/articles/PMC12216184/
- pmc.ncbi.nlm.nih.gov/articles/PMC11850796/
- pmc.ncbi.nlm.nih.gov/articles/PMC12852416/
- pmc.ncbi.nlm.nih.gov/articles/PMC5556182/
- pmc.ncbi.nlm.nih.gov/articles/PMC5556182
- pmc.ncbi.nlm.nih.gov/articles/5556182/
- pmc.ncbi.nlm.nih.gov/articles/PMC7053614/
- clinicaltrials.gov/search?term=FOXO4-DRI
- fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-c
Reddit threads read · 10
- r/PeptideForum
- r/Peptidesource
- r/Biohackers
- r/Peptides
- r/Peptides
- r/Peptidesource
- r/Peptides
- r/Biohackers
- r/PeptideDiscussion
- r/PeptideTides
5 further sources on commercial or non-primary hosts not listed.
Research checked 2026-11-13.